Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guyatt, G.
Right arrow Articles by Newhouse, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Guyatt, G.
Right arrow Articles by Newhouse, M.

Chest, Vol 92, 618-620, Copyright © 1987 by American College of Chest Physicians

ARTICLES

A controlled trial of ambroxol in chronic bronchitis

GH Guyatt, M Townsend, F Kazim and MT Newhouse
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.

Ambroxol is a mucolytic agent which is widely used in chronic bronchitis in Europe. We conducted a double-blind randomized controlled trial of ambroxol vs matched placebo in 90 patients with chronic bronchitis and difficulty clearing secretions. It was concluded that there was no advantage to taking ambroxol.


This article has been cited by other articles:


Home page
 ChestHome page
D. J. Kellerman
P2Y2 Receptor Agonists* : A New Class of Medication Targeted at Improved Mucociliary Clearance
Chest, May 1, 2002; 121(5_suppl): 201S - 205S.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American College of Chest Physicians.